Compare MAGN & PTHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MAGN | PTHL |
|---|---|---|
| Founded | 1864 | 1998 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Paper | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.6M | 8.8M |
| IPO Year | N/A | 2024 |
| Metric | MAGN | PTHL |
|---|---|---|
| Price | $14.13 | $0.57 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 106.5K |
| Earning Date | 11-19-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,204,000,000.00 | $448,196.00 |
| Revenue This Year | $5.74 | N/A |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 46.50 | N/A |
| 52 Week Low | $7.82 | $0.47 |
| 52 Week High | $23.19 | $32.00 |
| Indicator | MAGN | PTHL |
|---|---|---|
| Relative Strength Index (RSI) | 72.15 | 40.28 |
| Support Level | $13.74 | $0.56 |
| Resistance Level | $14.85 | $0.63 |
| Average True Range (ATR) | 0.84 | 0.05 |
| MACD | 0.36 | 0.01 |
| Stochastic Oscillator | 88.41 | 21.35 |
Magnera Corp is a supplier of a diverse portfolio of specialty materials comprised of organic and synthetic raw ingredients. The company markets its own products predominantly into stable, consumer-oriented end markets, including wipes, healthcare, adult incontinence, apparel, baby, feminine care, air filtration, and food and beverage, for disposable and durable applications. It also provides technical solutions in infrastructure markets. The company's operations are organized into two operating and reportable segments: Americas and Rest of World. It derives the majority of its revenue from the Americas, which manufactures products and components of personal care, including medical garments, wipes, dryer sheets, filtration, baby diapers and adult incontinence.
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.